The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH MM 2018 | Vaccines to prevent progression or relapse in multiple myeloma
Ann van de Velde, MD, PhD, from Antwerp University Hospital, Antwerp, Belgium discusses the use of an autologous dendritic cell vaccination for multiple myeloma (MM). In addition, Dr van de Velde highlights the value of developing the vaccine, including the benefits of a low toxicity and short preparation time, and covers its cost relative to other novel treatments. This interview took place at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.
